Knopp Kevin J. sold $284K of MASS

Knopp Kevin J. (President and CEO) sold 27,622 shares of 908 Devices Inc. (MASS) at an average of $10.27 ($10.06–$10.35, $0.28M total) across 2 trades over 2026-08-13 to 2026-08-17 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Knopp Kevin J.
Published Aug 17, 2026, 9:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 17, 2026, 10:16 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$MASS
Neutral
medium confidence
Mentioned
$MASS
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MASSNeutralLow
01

Why it matters

The CEO’s open-market sale of 27,622 shares, executed under a pre-arranged 10b5-1 plan, is primarily a sentiment datapoint and typically has limited fundamental impact absent other news.

02

Market read

Traders may note the insider selling activity, but there is no new operational or financial catalyst in the text.

03

What to watch

The filing does not state reasons for sale beyond the plan; without accompanying changes in guidance, financing, or operations, the signal is weak.

Relevance 3/10Novelty 3/10Timing: filed 2026-08-17, covering sales from 2026-08-13 to 2026-08-17

Background

The article is an SEC Form 4 insider transaction disclosure for 908 Devices Inc. (MASS).

Company-level read

Ticker impact

$MASSNeutralMedium confidence
Context

SEC Form 4 shows MASS CEO Kevin J. Knopp sold 27,622 shares in open-market transactions at about $10.06 to $10.35.

Expected impact

Likely limited near-term impact; any effect should be small and sentiment-driven rather than a re-rating catalyst.

Evidence & confidence

The filing is a routine insider transaction with stated 10b5-1 pre-arrangement, and it does not include new company performance, guidance, or regulatory developments.

Market effects

No sector-level implications are disclosed; this is company-specific insider trading data.

None indicated.

None indicated.

Counterpoint

Because the sale is under a 10b5-1 plan, it may reflect scheduled liquidity rather than negative expectations, so traders may discount it.

Key entities

  • 908 Devices Inc.

    Company whose CEO filed the Form 4 insider sale disclosure.

  • Kevin J. Knopp

    President and CEO who sold shares under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$MASSHigh

908 Devices Inc (MASS) (Q3 2026) Earnings Call Highlights: Record $19 Million Revenue

908 Devices Inc (MASS) reported Q3 2026 revenue of $19M, up 35% YoY, driven by FTIR products and NearLab sales. The company raised full-year revenue guidance to $68.5M-$70M. Adjusted EBITDA loss narrowed to $1.7M, but gross margin decreased to 58%. MASS shipped 300+ devices, bringing the installed base to 4,400. NearLab integration is progressing, with 100 devices sold in Q3. The company remains unprofitable, with a net loss of $4.6M and $2.4M cash burn.

$MASSMed

908 Devices Q3 2026 slides: 35% growth, raised guidance

908 Devices (NASDAQ:MASS) reported 35% YoY revenue growth to $19.0M in Q3 2026, raising full-year guidance to $68.5M-$70.0M. Shares fell 4.43% premarket. The company focuses on chemical detection tools for public safety and defense, with FTIR products contributing 55% of revenue. Despite narrowing losses, concerns remain over customer concentration and adjusted EBITDA losses.

$MASSMed

908 Devices Reports Third Quarter 2026 Financial Results and Achieves Record Revenue

908 Devices Inc. (MASS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 ​ ​ 908 Devices Reports Third Quarter 2026 Financial Results and Achieves Record Revenue Revenue increased 35% compared to prior year Raises low end of 2026 revenue outlook ​ ​ BURLINGTON, Mass. – November 10, 2026 – 908 Devices Inc. (Nasdaq: MASS), a core small-cap

$MASSMed

908 Devices Inc. Q2 2026 Earnings Call Summary

908 Devices reported Q2 2026 revenue up 23%, driven by U.S. state and local demand for fentanyl and synthetic drug detection. VipIR saw 35+ shipments, and the NIRLAB acquisition added an AI subscription model. Full-year 2026 revenue guidance was raised to $68m-$70m. Adjusted EBITDA loss narrowed 50% YoY; recurring revenue target is 30%+.

$MASSMedAI 8/10

908 Devices Q2 Earnings Call Highlights

908 Devices (NASDAQ: MASS) reported Q2 operating expenses of $21.2M, down from $21.5M, and narrowed net loss from continuing operations to $11.9M. Adjusted EBITDA loss improved to $1.9M. Cash and marketable securities were $101.5M with no debt. The company raised 2026 revenue guidance to $68M-$70M and expects recurring revenue of $4.9M (31%).